Survey of Pentazocine Addiction and Opioid Use in Adult Sickle Cell Anaemia Patients: The Perspective of Healthcare Providers

-
Background: Sickle cell anaemia (SCA) is characterized by episodes of bone pain creating a major role for analgesic therapy in the emergency management of this condition. Opioids, including pentazocine, is used in some cases and may be addictive with prolonged use. Aim: This study aims to assess the scope of opioid use; pentazocine addiction and availability of resources for its management. Materials and Methods: This study was conducted using a 10-item pre-tested and pre-validated questionnaire which was administered to medical doctors working in haematology units across Nigeria. Results: 55 doctors involved in SCA patient care in 25 Nigerian health institutions with 13,314 registered SCA patients responded. The 5-year prevalence rate of pentazocine addiction was 2.9%. In managing pain in these patients, pentazocine ranked 2nd (21.2%) as the drug of choice after NSAIDs (26.9%). Majority of the physicians (48.1%) frequently prescribed DF118 while about 80% of them rarely prescribed morphine. Most of the doctors (61.8%) routinely counselled their patients on the dangers of opioid use, 88.9% believed there was need to adopt a guideline for opioids use and 89.1% agreed that pentazocine addiction was a major health challenge. 90.9% of the participants had neuropsychiatry units in their institutions, 71.2% of them accepted to have adequate neuropsychiatry staff and facilities.Conclusion: Pentazocine addiction in was thought to be a major heath challenge by majority of the managing physicians. They also agreed that there was a need to provide guidelines/ policies for opioid use as well as restriction of access to opioids by unauthorized persons while encouraging multidisciplinary approach in the management of pain.

Follow the link for full article
https://medwinpublishers.com/HIJ/HIJ16000133.pdf

Popular posts from this blog

Cladribine an Alternative for Midostaurine in FLT3 Positive Acute Myeloid Leukemia

-
Midostaurin is registered for the indication newly diagnosed acute myeloid leukemia that is FLT3 mutation positive in combination with standard cytarabine and daunorubicine induction and cytarabine consolidation. The registration is based on a study of 717 patients that examined the addition of midostaurin 50 mg orally twice daily or placebo to standard induction on days 8 to 21 of a cycle for a maximum of two induction cycles. Follow the link for full article https://medwinpublishers.com/HIJ/HIJ16000134.pdf
Read more

What Clinicians Should Know About the Use of Albumin

-
The advantages of albumin over less costly alternative fluids continue to be debated. Many scientific articles were devoted to the clinical analysis of the use of albumin in acute illness as well as its comparison with other fluid regimens. However, the lack of fundamental knowledge about the physical and chemical properties of commercial albumin generates many unpromising discussions about the effectiveness of the use of albumin among practitioners and medical scientists. The manuscript provides information about the different variants of commercial albumin, the mechanisms of their action, indications and contraindications to use. The presented information is based on fundamental knowledge of physical and chemical properties of commercial albumin. This manuscript is not only educational information, but also is guide to action for clinicians. Follow the link for full article https://medwinpublishers.com/HIJ/HIJ16000139.pdf
Read more

Where do we Position Transfusion Medicine in the Family of Sciences?

-
Transfusion Medicine has come a long way and has for long been regarded a Cinderella in medicine and medical science. Since the discovery around 1900 by Karl Landsteiner of the ABO blood groups as principle elements for compatibility, the science has been dominated by the laboratory research for immunohematology, microbiology and virology, focused on the test tube and not so much the patient. Over the 20st century several development eras are to be recognized that contributed to the maturation of transfusion medicine as a bridging science. Twenty Nobel laureates contributed to this development. Follow the link for full article https://medwinpublishers.com/HIJ/HIJ16000137.pdf
Read more